Published: June 19th 2024 | Updated: June 24th 2024
Utilizing Biomarkers to Develop First-in-Class Antibody Drug Conjugates to Treat Advanced Solid Tumors
Published: July 25th 2025 | Updated: August 1st 2025
Replimune CRL Fallout: How Biopharma Leaders Should Manage a New Layer of FDA Uncertainty
Published: July 21st 2025 | Updated: August 1st 2025
Emrelis and the Evolving Landscape of Antibody Drug Conjugates
Published: July 22nd 2025 | Updated: August 1st 2025
Emrelis Approval Highlights FDA Confidence in ADC Oncology Treatments
Published: July 8th 2025 | Updated: August 1st 2025
Advancing Innovation in Cancer Care: Bringing the Next Wave of Oncology Products to Market
Published: June 24th 2025 | Updated: August 1st 2025
Developing FP&A Strategies in Today’s Environment: Q&A with Jennifer Kyle